The ubiquitously expressed glucocorticoid receptor (GR) is a major drug target for 31 inflammatory disease, but issues of specificity, and target tissue sensitivity remain. 32
Introduction 50
Synthetic glucocorticoids (Gc) are potent anti-inflammatory drugs used to treat 51 multiple conditions including asthma and rheumatoid arthritis (Schett et al., 52 2008; Krishnan et al., 2009) . Unfortunately Gc treatment also carries a wide range of 53 serious side effects including hyperglycaemia and osteoporosis (Canalis et al., 2002) . 54
In recent years a significant effort has been made to design dissociative ligands with 55 the anti-inflammatory potency of conventional Gc, but with a reduced spectrum of 56 side-effects (Lin et 1985;Encio and tera-Wadleigh, 1991). The unliganded GR resides in the cytoplasm in 64 a complex with heat-shock proteins and immunophilins (Grad and Picard, 2007) . 65
Ligand binding triggers rapid activation of cytosolic kinase signalling cascades and 66 concomitantly results in exposure of two nuclear localisation signals (NLS1, and 67 NLS2) enabling nuclear import (Picard and Yamamoto, 1987) . This is accompanied 68 by replacement of the immunophilin FKBP51 with FKBP52 (Davies et al., 2002 ) 69 which associates with dynein to drive GR along microtubules (Czar et al., 70 1994; Harrell et al., 2004) . The process of translocation to the nucleus post ligand 71 binding occurs rapidly, with the majority of cellular GR being nuclear 30 minutes 72 after treatment with 100nM Dex (Nishi et al., 1999) . In addition cell cycle phase is 73 able to regulate the subcellular localisation of unliganded GR, but with far slower 74 kinetics of nuclear accumulation (Matthews et al., 2011) . In the nucleus GR binds to 75 cis-elements to activate or repress target gene expression, recruiting co-modulator 76 proteins from distinct classes to effect chromatin remodelling, and recruitment of the 77 basal transcriptional machinery (Ford et Here we identify a novel switch mechanism that regulates GR trafficking in response 96 to ligand binding, distinct from an effect attributable to ligand potency. We identify 97 two novel, non-steroidal GR ligands that regulate the GR surface to greatly reduce 98 rates of nuclear translocation and reduce reliance on heat-shock protein for continuing 99 activity. The difference in GR conformation induced by the novel GR ligands reveals 100 a patch of positive charge on the surface of the LBD. We propose that this prevents 101 efficient engagement with the active nuclear translocation mechanism, subsequent 102 export, and protein degradation mechanisms for the GR. The result is generation of 103 ligands with greatly prolonged duration of action as a consequence of altered 104 pharmacodynamics rather than pharmacokinetics. membranes were incubated with a species-specific horseradish peroxidase-conjugated 138 secondary antibody (diluted in wash buffer) for 1 hour at room temperature, and 139 washed a further three times, each for 10 minutes. Immunoreactive proteins were 140 visualised using enhanced chemiluminescence (ECL Advance, GE Healthcare). 141
142
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Reporter gene assays 143
HeLa cells seeded in DMEM containing sFCS were co-transfected with 2 g reporter 144 gene and 0.5 g CMV-renilla luciferase (to correct for transfection efficiency) using 145
Fugene 6 (Roche Diagnostics, West Sussex, UK) at a ratio of 3:1 (v/w). 24 hours post 146 transfection, cells were treated as specified in results prior to lysis, then assayed for 147 luciferase activity using a dual-luciferase reporter assay system following the 148 manufacturer's instructions (Promega, Southampton, UK with Hoeschst (Sigma) in PBS (2 g/ml) for 20 minutes at 4 ˚C. Following three 5 163 minute washes in PBS, coverslips were mounted using Vectamount AQ (Vector 164 Laboratories, Peterborough, UK). Images were acquired on a Delta Vision RT 165 (Applied Precision, GE Healthcare) restoration microscope using a 40X/0.85 Uplan 166
Apo objective and the Sedat Quad filter set (Chroma 86000v2, VT, USA). The images 167 were collected using a Coolsnap HQ (Photometrics, AZ, USA) camera with a Z 168 optical spacing of 0.5μm. Raw images were then deconvolved using the Softworx 169 software (GE Healthcare) and average intensity projections of these deconvolved 170 images processed using Image J (Rasband, 1997 
MTS Assay 194
Cells were seeded into a 96 well plate were treated as described in the results. Crystal structures 1M2Z and 3E7C were superposed and conformations of residues 248 within 6 Angstrom of the Dex ligand in 1M2Z were compared visually. Any differing 249 substantially were coloured differently ( Fig. 2A, B) , and these atom colours projected 250 onto a molecular surface to reveal regions of the protein surface impacted by the 251 residue movements induced by binding of GSK47866A ( 
GSK47867A and GSK47869A, are highly potent GR agonists 266
There is wide interest in understanding how variation in ligand structure (Fig. 1A ) 267 affects the function of GR. Here, we use novel, non-steroidal glucocorticoid receptor 268 ligands (NSG) with very high potency, and specificity for GR to determine how 269 ligand structure impacts receptor function (Fig. 1, B-C Fig. S1 ). Transient GR 270 transactivation and transrepression models in HeLa cells were used initially to 271 compare the NSGs to conventional synthetic Gc ligands. We find that both 272 GSK47867A and GSK47869A were approximately 30 times more potent that 273 Dexamethasone (Dex, Fig. 1B -C, table 1). Similar results were also obtained using 274 A549 cells with stably integrated GRE-Luc or NFκB-Luc templates ( Fig. S2A-B) . 275
The steroidal Gc Fluticasone Propionate (FP) had similar potency to GSK47867A and 276 GSK47869A. Hydrocortisone was significantly less potent than all the synthetic 277 ligands tested (Fig. 1) . 278
279
To rationalise subsequent matched analyses, saturating concentrations of the ligands 280 were selected, calculated as 10 times the measured EC50 for transactivation (Table 1) . 281
At these concentrations all ligands showed similar repression of IL6 and IL8 secretion 282 ( Fig. S2C-D) , and inhibition of cell proliferation ( Fig. S2E-F) . 283
284
GR crystal structure reveals ligand-specific altered surface charge 285
To identify conformational differences in the GR ligand binding domain (LBD), we 286 first compared the structures of GR-Dex (1M2Z) and GR-GSK47866A (3E7C) a non-287 steroidal GR ligand similar in structure to GSK47867A (Figs 1A, 2). An active site 288 model derived from the coordinates of deposited structure 3E7C was used to dock 289 GSK47867A and GSK47869A. Both GSK47867A and GSK47869A are similar to 290 GSK47866A and gave very high scoring fits in the binding pocket formed by 291 GSK47866A bound to the GR LBD ( Fig. S4C-D) . The 298 greatest displacement was seen in amino acids Gln570 and Arg611 (Fig. 2C-D) . Less 299 displacement was seen at the opposite end of the ligand; most noticeable here was the 300 movement of Gln642 (Fig. S4C-D) . The effect of residue movements in the GR LBD 301 upon binding of GSK47866A was examined by visualisation of the molecular surface 302 (Fig. 3, Fig. S5 and S6 ). This revealed a distinct surface electrostatic potential 303 difference, highlighting a patch of positive charge in the GR-GSK47866A structure 304 resulting from displacement of Arg611 (Fig. 3 B,D) . This demonstrates that the 305 structural difference between Dex and the NSGs results in a different GR surface 306 charge upon binding, with potential for altered for protein-protein interactions. 307
308
NSG induce different kinetics of endogenous Gc target gene regulation 309
To determine whether the alteration in GR surface charge upon binding NSG had any 310 functional consequence, transcript levels of endogenous Gc induced (GILZ and 311 FKBP5) and Gc repressed (IL6 and IL8) target genes were quantified at multiple time 312 points ( Fig. 4A-B, Fig. S7A-B) . Both the steroidal and NSG ligands displayed 313 equivalent kinetics of FKBP5 induction (Fig. 4A) . Although NSG treatment did not 314 induce GILZ transcript at 1 hour, similar induction was observed at later time points 315 (Fig. 4B) . Similarly NSG treatment did not repress IL6 or IL8 transcripts at 1 hour but 316 comparable repression was observed at later time points (Fig. S7A-B) . 317
318
NSG treatment results in delayed kinetics of GR 211 phosphorylation 319
Transactivation of IGFBP1 is reliant on Ser211 phosphorylation of the GR, a signal to 320 recruit the co-activator protein MED14. Dex treatment resulted in significant 321 induction of IGFBP1 transcript by 1 hour (Fig. S8A ), but the NSG ligands failed to 322 induce transcript at this early time point. This lack of transcript regulation at an early 323 time point was similarly seen with GILZ, IL6 and IL8. Ligand induction of GR 324
Ser211 phosphorylation was compared. Treatment with Dex resulted in rapid 325 phosphorylation of GR at both serine residues 203 and 211 (Fig. S8B) . The NSG 326 ligands induced slower onset of phosphorylation of both serine residues 203 and 211 327 (Fig. S8B) . 328
329
NSG treatment results in slow rate of GR nuclear translocation 330
The delay in endogenous gene transactivation and receptor phosphorylation seen with 331 NSG treatment suggested that nuclear translocation may also be delayed. Use of a 332
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halo tagged GR clearly demonstrated a slower rate of nuclear translocation with both 333 GSK47867A and GSK47869A (Fig. 4C ). Ligand-bound nuclear GR has a signature 334 FRAP signal, with reduced intranuclear mobility resulting in delayed recovery from 335 photobleaching. FRAP studies revealed that at 1 hour following NSG treatment 336 nuclear GR displayed characteristics of an unliganded receptor (Fig. S9A-B) . 337
However with 4 hour NSG treatment nuclear GR displayed the typical signature of 338 liganded receptor, indicative of a delay in adoption of the activated GR conformation 339 (Fig. S9C-D) . 340
Altered kinetics of GR phosphorylation may explain the observed differences in 341 nuclear translocation rate and transactivation of endogenous Gc target genes. 342 Therefore, we made GR mutants Ser211Ala (phosphodeficient) and Ser211Asp 343 (phosphomimetic) to assess the importance of this phosphorylation site (Fig. S10A) . 344
However, the phosphomimetic GR did not significantly increase the rate of GR 345 translocation with either GSK47867A or GSK47869A treatment ( Fig. S10C-D) . 346
Likewise the phosphodeficient GR had no significant impact on the rate of 347 translocation seen with Dex treatment (Fig. S10B, D) . (Fig. 4D) . This revealed that the NSG ligands 354 consistently took longer to reach half-maximal transactivation compared to either 355 Dex, or the higher potency FP (Fig. 4E) . Interestingly all three high potency ligands 356 resulted in greater maximal transactivation (Fig. 4D) . 357
358
Delayed action of NSG ligands cannot be explained by impaired cellular uptake 359
One possible explanation for these observations is altered ligand access to the 360 intracellular GR. Initially mass spectroscopy analysis of cell lysates was performed 361 after 10 minutes ligand exposure (Fig. 5A) . A 10M concentration of each ligand 362 was compared, to permit detection of the ligand by mass spectrometry in cell lysates. 363 Strikingly, the NSG ligands showed greater than 10 fold increased concentrations 364 within the cells compared to Dex, effectively ruling out delayed ligand penetration. 365
To further evaluate cell pharmacokinetics, cells were incubated with 100 nM Dex or 366 3 nM FP, GSK47867A or GSK47869A for 10 minutes, washed and then incubated in 367 ligand-free medium for 4 hours. These samples were compared to cells treated with 368 ligand continuously for 4 hours (Fig. 5B-D) . Short exposure to both NSG ligands 369 resulted in greater induction of GILZ and FKBP5 although not IGFBP1 compared to 370
Dex, again demonstrating rapid cellular accumulation of ligand. Furthermore cells 371 incubated with NSG on ice for 1 hour to permit ligand access in the absence of GR 372 activation still showed delayed nuclear translocation (Fig. 5E-F) , implicating a post 373 receptor mechanism of action. The observed differences could not be attributed to 374
Dex activation of mineralocorticoid receptor, as the mineralocorticoid receptor 375
antagonist Spironolactone did not affect the Dex induction (Fig. S11A-B) . 376
377
NSG bound GR shows prolonged nuclear retention 378
As treatment with both NSG ligands results in delayed nuclear translocation, we 379 investigated whether nuclear export of GR may also be slower. To measure GR export 380 HeLa cells were treated with 100 nM Dex or 3 nM NSGs for 1 hour then washed and 381 placed in serum free media and imaged over 24 hours (Fig. S12A) . In cells treated 382 with NSG the GR-GFP was not exported from the nucleus during the 24 hour wash-383 out period, but Dex treated cells exported GR from the nucleus within 6 hours ( and co-workers (Ricketson et al., 2007) as important for HSP90 interaction were 395 mapped onto the crystal structure of GR bound to Dex (Fig. 6A) . Surface map 396 analysis of GR following replacement of Met604 with Thr604, which has been shown 397 to inhibit HSP90 recruitment, was in the same part of the GR structure that was 398 differentially affected by NSG binding (Fig. 6B, C) . 399
Microtubule disruption improves nuclear translocation rate 401 HSP90 anchors the GR to the microtubule network, so permitting rapid, energy-402 dependent nuclear translocation. HSP90 antagonism slows the rate of nuclear 403 translocation (Galigniana et al., 1998) . However, in addition, GR can translocate 404 using a diffusion mechanism (Nishi et al., 1999) . Disruption of the microtubule 405 network using colcemid restores rapid GR translocation even in the presence HSP90 406 inhibitor geldanamycin (Segnitz et al., 1997; Galigniana et al., 1998) . Therefore, we 407 used colcemid to determine if the microtubule architecture was slowing NSG 408 mediated nuclear translocation. Colcemid significantly increased the rate of NSG-409 driven nuclear translocation, but had no effect on that promoted by Dex (Fig. 6D-G) , 410 suggesting a diffusion mechanism for translocation 411
412
NSGs mediate prolonged duration of action 413
The duration of ligand-dependent activity depends on continuing presence of ligand, 414
and maintaining GR in a ligand-binding compatible conformation. To investigate 415 these phenomena we initially undertook washout studies, using real time reporter gene 416 luciferase analysis. These revealed a striking prolongation of transactivation following 417 NSG ligand withdrawal compared to either Dex or FP, which was not explained by 418 increased ligand potency (Fig. 7A) . 419
To corroborate these observations with endogenous genes a two hour ligand exposure 420 was chased with a 24 hour washout before measurement of GILZ and FKBP5 421 transcripts (Fig 7B-C) . There was significantly enhanced preservation of 422 transactivation seen with both the NSGs compared to the potency matched control 423 steroid FP. 424
To determine the role of HSP90 in mediating prolonged GR transactivation, 425 geldanamycin was used. As HSP90 activity is required for initial GR ligand binding, 426 these studies were performed sequentially, adding geldanamycin after ligand 427 activation. The geldanamycin was added to cells at the time of maximal 428 transactivation, in the presence of continuing ligand exposure (Fig. 7D) . Both FP and 429
Dex showed exponential decay of transactivation, as predicted. However, the NSG 430 ligands showed a striking biphasic response, with initial potentiation, followed by 431 decay (Fig. 7D) . 432
As HSP90 is also essential for maintaining GR protein stability investigation of 433 receptor abundance and phosphorylation was undertaken. Inhibition of HSP90 434 preserves GR protein levels following Dex treatment for 4 hours (Fig. 7E) , but not at 435 a later time point (Fig. 7F) . Strikingly, the NSG ligands did not show such a ligand-436 dependent loss of GR protein (Fig. 7E,F) , again identifying differences in HSP90 437 interaction with the novel NSGs. Additionally treatment of cells with Dex in the 438 presence of geldanamycin results marked dephosphorylation of GR at serine 211 (Fig.  439   7E ). However treatment with the NSG was protective for serine 211 phosphorylation 440 (Fig. 7E) . Collectively, these studies suggest that GR-HSP90 interactions can be 441 modulated by ligand structure, to influence the properties of the Gc response. (Fig. 7G) , and contains a peptidylprolyl isomerase domain that is capable of 530 dynein interaction and therefore forming a bridge between the GR and the nuclear 531 export machinery (DeFranco et al., 1991; Galigniana et al., 2002) (Fig. 7G) . 532 Therefore, as PP5 has been implicated in the nuclear export of the GR, the lack of 533 dephosphorylation seen with NSG treatment is compatible with a broader change in 534 protein recruitment with the NSG ligands. Interestingly, it was also observed that 535 NSG treatment preserved GR protein expression compared with Dex treatment. This 536 would further suggest that the conformation adopted by GR following NSG binding 537 decouples protein recruitment required for terminating the GR transcriptional signal 538 (Nawaz and O'Malley, 2004) (Fig 7G) . 539 540 In conclusion we have identified two NSGs that bind to GR with high specificity but 541 paradoxically result in profoundly slowed kinetics of cellular response. Analysis of 542 the structural effects of these NSGs bound to GR suggests a change to the GR surface, 543 through the movement of Arg611 in the ligand binding pocket of the GR, resulting in 544 an alteration in the GR surface charge. The change in electrostatic charge is close to 545 the known binding site for HSP90, and co-modulator proteins. This alteration carries 546 with it the consequence of delayed GR phosphorylation and nuclear translocation, 547 which in turn results in delayed early Gc target gene regulation. 
